Intranasal vaccines: Forthcoming challenges

Pharmaceutical Science and Technology Today

Volumn 3, Issue 8, 2000, Pages 273-281

  Partidos, Charalambos D ^a  

^a INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; LIPOSOME; VACCINE;

ANTIBODY RESPONSE; CELLULAR IMMUNITY; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; IMMUNIZATION; IMMUNOGENICITY; INTRANASAL DRUG ADMINISTRATION; NONHUMAN; NOSE MUCOSA; REVIEW;

EID: 0034254822     PISSN: 14615347     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1461-5347(00)00281-9     Document Type: Review

References (86)

1. McGhee, J.R. et al. (1992) The mucosal immune system: From fundamental concepts to vaccine development. Vaccine 10, 75-88
2. Kuper, C.F. et al. (1992) The role of nasopharyngeal lymphoid tissue. Immunol. Today 13, 219-224
3. Koornstra, P.J. et al. (1991) The Waldeyer ring equivalent in the rat. A model for analysis of oronasopharyngeal immune responses. Acta Otolaryngol 111, 591-599
4. Rerry, M. and Whyte, A. (1998) Immunology of the tonsils. Immunol. Today 19, 414-420
5. Neutra, M.R. et al. (1996) Antigen sampling across epithelial barriers and induction of mucosal immune responses. Annu. Rev. Immunol. 14, 275-300
6. Gizurarson, S. et al. (1991) The effect of cholera toxin and cholera toxin B subunit on the nasal mucosal membrane. Vaccine 9, 825-832
7. Willoughby, J.B. and Willoughby, W.F. (1977) In vivo responses to inhaled proteins. Quantitative analysis of antigen uptake, fate and immunogenicity in a rabbit model system. J. Immunol. 119, 2137-2146
8. Hoyne, G.F. et al. (1993) Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitised mice. J. Exp. Med. 178, 1783-1788
9. Tian, J. et al. (1996) Nasal administration of glutamatedecarboxylase (GAD65) peptide induces Th2 responses and prevents murine insulin dependent diabetes. J. Exp. Med. 183, 1561-1567
10. Wu, H-H. et al. (1997) Nasal lymphoid tissue (NALT) as a mucosal immune inductive site. Scand. J. Immunol. 46, 506-513
11. McGhee, J.R. and Kiyono, H. (1992) Mucosal immunity to vaccines: Current concepts for vaccine development and immune response analysis. In Advances in Experimental Medicine and Biology (Ciardi, J.E. et al., eds), pp. 3-12, Plenum Press
12. Mestecky, J. and McGhee, J.R. (1987) Immunoglobulin A (IgA): Molecular and cellular interactions involved in IgA biosynthesis and immune response. Adv. Immunol. 40, 153-245
13. Czinn, S.J. et al. (1993) Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization. Vaccine 11, 637-642
14. Mazanec, M.B. et al. (1987) Immunoglobulin A monoclonal antibodies protect against Sendai virus. J. Virol. 61, 2624-2626
15. Kilian, M. et al. (1988) Defence mechanisms involving Fc-dependent functions of immunoglobulin A (IgA) and their subversion by bacterial immunoglobulin A proteases. Microbiol. Rev. 52, 296-303
16. Quiding-Jarbrink, M. et al. (1995) Human circulating antigen-specific B cell immunoblasts after mucosal and systemic immunizations: Differential homing commitments and cell surface differentiation markers. Eur. J. Immunol. 25, 322-327
17. Daynes, R.A. et al. (1990) Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T-helper cell function. J. Exp. Med. 171, 979-996
18. Mosmann, T.R. and Coffman, R.L. (1989) Th1 and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7, 145-173
19. Czerkinsky, C. et al. (1991) Detection of human cytokine-secreting cells in distinct anatomical compartments. Immunol. Rev. 119, 5-22
20. Yap, K.L. et al. (1978) Transfer of specific cytotoxic lymphocytes protects mice inoculated with influenza virus. Nature 238, 238-239
21. Lukacher, A.E. et al. (1984) In vivo function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific. J. Exp. Med. 160, 814-826
22. Munoz, J.L. et al. (1991) Respiratory syncytial virus infection in C57BL/6 mice: Clearance of virus from the lungs with virus-specific cytotoxic T cells. J. Virol. 65, 4494-4497
23. Crowe, J.E. (1999) Host responses to respiratory virus infection and immunization. Curr. Top. Microbiol. Immunol. 27, 191-214
24. McDermott, M.R. and Bienenstock, J. (1979) Evidence for a common mucosal immunologic system. Migration of B immunoblasts into intestinal, respiratory, and genital tissues. J. Immunol. 122, 1892-1898
25. Mestecky, J. (1987) The common mucosal immune system and current strategies for induction of immune responses in external secretions. J. Clin. Immunol. 7, 265-276
26. Singh, M. and O'Hagan, D.T. (1999) Advances in vaccine adjuvants. Nat. Biotechnol. 17, 1075-1081
27. Spangler, B.D. (1992) Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56, 622-647
28. Elson, C.O. (1996) Cholera toxin as a mucosal adjuvant. In Mucosal Vaccines (Kiyono, H. et al., eds), pp. 59-72, Academic Press
29. Dickinson, B.L. and Clements, J.D. (1996) Use of Escherichia coli heat-labile enterotoxin as an oral adjuvant. In Mucosal Vaccines (Kiyono, H. et al., eds), pp. 73-87, Academic Press
30. Partidos, C.D. et al. (1996) Induction of measles-virus-specific cytotoxic T-cell responses after intranasal immunization with synthetic peptides. Immunology 87, 179-185
31. Partidos, C.D. et al. (1999) Heat-labile enterotoxin of Escherichia coli and its site-directed mutant LTK63 enhance the proliferative and cytotoxic T-cell responses to intranasally co-immunized synthetic peptides. Immunol. Lett. 67, 209-216
32. Lycke, N. et al. (1992) The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 22, 2277-2281
33. Pizza, M. et al. (1994) A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit. J. Exp. Med. 180, 2147-2153
34. Di Tommaso, A. et al. (1996) Induction of antigen specific antibodies in vagina secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect. Immun. 64, 974-979
35. Partidos, C.D. et al. (1996) The adjuvant effect of a non-toxic mutant of heat-labile enterotoxin of Escherichia coli for the induction of measles virus-specific CTL responses after intranasal co-immunization with a synthetic peptide. Immunology 89, 483-487
36. Douce, G. et al. (1997) Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect. Immun. 65, 2821-2828
37. Yamamoto, M. et al. (1998) A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A. J. Immunol. 161, 4115-4121
38. Giuliani, M.M. et al. (1998) Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J. Exp. Med. 187, 1-10
39. Yamamoto, M. et al. (1999) Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant. J. Immunol. 162, 7015-7021
40. Agren, L.C. et al. (1997) Genetically engineered non-toxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J. Immunol. 158, 3936-3946
41. Agren, L.C. et al. (1999) Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J. Immunol. 162, 2432-2440
42. Marinaro, M. et al. (1999) Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin. J. Immunol. 162, 114-121
43. Boyaka, P.N. et al. (1999) IL-12 is an effective adjuvant for induction of mucosal immunity. J. Immunol. 162, 122-128
44. Staats, H.F. and Ennis, F.A., Jr (1999) IL-1 is an effective adjuvant for mucosal and systemic immune responses when co-administered with protein immunogens. J. Immunol. 162, 6141-6147
45. Krieg, A.M. et al. (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546-549
46. Klimman, D. et al. (1996) CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secret IL-6, IL-12 and INF-gamma. Proc. Natl. Acad. Sci. U.S.A 93, 2879-2883
47. Bird, A.P. (1986) CpG-rich islands and the function of DNA methylation. Nature 321, 209-213
48. Roman, M. et al. (1997) Immunostimulatory DNA sequences function as T helper 1 promoting adjuvants. Nat. Med. 3, 849-854
49. Oxenius, A. et al. (1999) CpG containing oligonucleotides are efficient adjuvants for induction of protective anti-viral immune responses with T-cell peptide vaccines. J. Virol. 73, 4120-4126
50. McCluskie, M.J. and Davis, H.L. (1998) CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immunol. 161, 4463-4466
51. Moldoveanu, Z. et al. (1998) CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16, 1216-1224
52. Agrawal, S. (1996) Antisense oligonucleotides: Towards clinical trials. Trends Biotechnol. 14, 376-387
53. Liang, H. et al. (1996) Activation of human B cells by phosphorothioate oligodeoxynucleotides. J. Clin. Invest. 98, 1119-1129
54. Giannasca, P.J. et al. (1997) Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell directed lectins. Infect. Immun. 65, 10, 4288-4298
55. Medina, E. et al. (1998) Fibronectin-binding protein I of Streptococcus pyogenes is a promising adjuvant for antigens delivered by mucosal routes. Eur. J. Immunol. 28, 1069-1077
56. Schodel, F. and Hofnung, M. (1990) Oral immunization using recombinant bacteria. Res. Microbiol. 141, 745-1019
57. Stover, C.K. et al. (1991) Induction of antibody and T-cell responses to foreign antigens by recombinant BCG vaccines. Nature 351, 456-460
58. Langermann, S. et al. (1994) Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi. Nature 372, 552-555
59. Fennelly, G.J. et al. (1999) Mucosal DNA vaccine immunization against measles with a highly attenuated Shigella flexneri vector. J. Immunol. 162, 1603-1610
60. Dietrich, G. et al. (1999) Delivery of DNA vaccines by attenuated intracellular bacteria. Immunol. Today 20, 251-253
61. Piccini, A. and Paoletti, E. (1988) Vaccinia: Virus, vector, vaccine. Adv. Vir. Res. 34, 43-64
62. Smith, G.L. and Moss, B. (1983) Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene 25, 21-28
63. Bennink, J.R. and Yewdell, J.W. (1990) Recombinant vaccinia viruses as vectors for studying T lymphocyte specificity and function. In Poxviruses, Curr. Top. Microbiol. Immunol. (Moyer, R.W and Turner, P.C., eds), pp. 153-184, Springer-Verlag
64. Wild, T.F. et al. (1992) Construction of vaccinia virus recombinants expressing several measles virus proteins and analysis of their efficacy in vaccination of mice. J. Gen. Virol. 73, 359-367
65. Etchart, N. et al. (1996) Mucosal and systemic immune responses to measles virus haemagglutinin in mice immunized with a recombinant vaccinia virus. J. Gen. Virol. 77, 2471-2478
66. Graham, F.L. and Prevec, L. (1992) Adenovirus-based expression vectors and recombinant vaccines. In Vaccines: New Approaches to Immunological Problems (Ellis, R.W., ed.), pp. 363-390, Butterworth-Heinemann
67. Kozarsky, K.F. and Wilson, J.M. (1993) Gene therapy: Adenovirus vectors. Curr. Opin. Genet. Dev. 3, 499-503
68. Rosenthal, K.L. et al. (1996) Recombinant adenoviruses as vectors for mucosal immunity. In Mucosal Vaccines (Kiyono, H. et al., eds), pp. 147-158, Academic Press
69. Scott-Gallichan, W. and Rosenthal, K.L. (1996) Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J. Exp. Med. 184, 1879-1890
70. Gallichan, W.S. et al. (1993) Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex glycoprotein B. J. Infect. Dis. 168, 622-629
71. Belyakov, I.M. et al. (1999) Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by pre-existing poxvirus immunity. Proc. Nat. Acad. Sci. U.S.A. 163, 184-193
72. Vadolas, J. et al. (1995) Intranasal immunization with liposomes induces strong mucosal immune responses in mice. Eur. J. Immunol. 25, 969-975
73. Gregoriadis, G. (1990) Immunological adjuvants: A role for liposomes. Immunol. Today 11, 89-97
74. Klavinskis, L. et al. (1999) Intranasal immunization with plasmid DNA - Lipid complexes elicits mucosal immunity in the female genital and rectal tracts. J. Immunol. 162, 254-262
75. Morein, B. et al. (1984) ISCOM: A novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308, 457-460
76. Mowat, A.M. and Donachie, A.M. (1991) ISCOMS - A novel strategy for mucosal immunization? Immunol. Today 12, 383-385
77. Johanson, M. and Lovgren-Bengtsson, K. (1999) Iscoms with different quillaja saponin components differ in their immunomodulating activities. Vaccine 17, 2894-2900
78. Eldridge, J.H. et al. (1991) Biodegradable microspheres as a vaccine delivery system. Mol. Immunol. 28, 287-294
79. Marx, P.A. et al. (1993) Protection against vaginal SIV transmission with microencapsulated vaccine. Science 260, 1323-1327
80. Partidos, C.D. et al. (1996) Biodegradable microparticles as a delivery system for measles virus cytotoxic T-cell epitopes. Mol. Immunol. 33, 485-491
81. Men, Y. et al. (1996) Induction of sustained and elevated immune responses to weakly immunogenic synthetic malaria peptides by incorporation in biodegradable polymer microspheres. Vaccine 14, 1442-1450
82. Jones, D.H. et al. (1997) Poly (DL-lactide-coglycolide) encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded proteins after oral administration. Vaccine 15, 814-817
83. Singh, M. et al. (2000) Cationic microparticles: A potent delivery system for DNA vaccines. Proc. Natl. Acad. Sci. U.S.A. 97, 2, 811-816
84. Duncan, J.D. et al. (1996) Poly(lactide-co-glycolide) microencapsulation of vaccines for mucosal immunization. In Mucosal Vaccines (Kiyono, H. et al., eds), pp. 159-173, Academic Press
85. Almeida, A.J. et al. (1993) Immune responses to nasal delivery of antigenically intact tetanous toxoid associated with poly(L-lactic acid) microspheres in rats, rabbits and guinea-pigs. J. Pharm. Pharmacol. 45, 198-203
86. Ray, R. et al. (1993) Microencapsulated human parainfluenza virus induces a protective immune response. J. Infect. Dis. 167, 752-755